Artemis Funds (Lux) – US Select update

Cormac Weldon and Chris Kent managers of the Artemis Funds (Lux) – US Select, report on the fund over the year to 31 December 2023.

Cormac Weldon

Source for all information: Artemis as at 31 December 2023 unless otherwise stated.

The fund returned 11.7% over the quarter, in line with the S&P 500 index

Inflation in check?

As had been the case for most of the year, markets were fixated on inflation and the likely path the Federal Reserve would take in response to its trajectory. At the start of the quarter, it was widely accepted by the market that rates would remain higher for longer to combat stubborn inflation.

As the quarter progressed, it became clear that CPI inflation was trending lower towards the Federal Reserve’s target of 2%, supported by softening demand and a more balanced employment dynamic. The Federal Reserve confirmed the market's expectations in December when they signalled a pause in rate hikes, and went further, forecasting three rate cuts of 0.25% in 2024.

Stock selection drives outperformance

In an environment where inflation and rates very much dominated markets, it was encouraging to see that stock selection across a variety of sectors was the main driver of performance over the period, underpinned by not only macro tailwinds but robust fundamental performance.

Amazon’s AWS recovers

Our overweight position in Amazon was our top contributor during the period. As the third quarter reporting season commenced, we were looking for expanded profitability in Amazon's retail business as well as a recovery from trough revenue growth within its cloud business, AWS. It was therefore encouraging to see overall profits significantly beating expectations with the margins of North American retail, international retail, and AWS showing significant improvement. Our conviction in the company remains strong with the expectation that AWS growth should accelerate into 2024.

Housing market enjoys structural support

If you have read or listened to us talk about exposures in the fund you will have heard us discuss our belief in the US housing sector.

There are multiple aspects to this thesis. Broadly, there is a structural shortage in housing inventory in the US. Most mortgages are not portable and home owners are reluctant to move from a low mortgage rate to a high mortgage rate, meaning that recently they have tended to remain in their current houses and so secondary supply does not come on the market. This means that demand must be met with new build, favouring housebuilders and suppliers of building materials. In addition, household formation (couples choosing to live together and possibly have children) is also picking up because of shifts in demographics.

Our holding in Builders FirstSource (a distributor of homebuilding products) forms part of this exposure and was a top contributor over the quarter. Eagle Materials (a manufacturer of cement and wallboard) also benefited from this theme.

Healthcare and energy lag

Energy was the only negative sector over the period, and so holdings in Baker Hughes (oil field services) and Hess (oil & gas) detracted from performance. We would add that we are underweight the sector, which was positive overall from a relative perspective.

Our holdings in healthcare stocks Thermo Fisher, Dexcom, and McKesson detracted over the period. We continue to see healthcare as a significant opportunity moving into 2024.

Activity

We have made several adjustments to the portfolio over the period, either because of strong share price performance or to better position the portfolio for an easing interest rate outlook.

While remaining overweight we have taken profits in both Nvidia and Meta, two of our strongest performers this year. Within financials we increased our position in Wells Fargo which we had bought in the last month or two. We also added to our position in Blackstone.

Outlook

First, we see the continuation of recovery in sectors we are already exposed to such as housing and infrastructure investment. In addition, we still think there are a couple of sectors which have not yet normalised following the pandemic. One of them is healthcare, where we expect the demand for life science products and services to recover to a more normal level. We expect our holding in Avantor to benefit from this.

Another potential recovery area is the memory-chip sector. After a boom in demand followed by a period of oversupply, pricing collapsed. We believe pricing is now stabilised, and is on the path to strong recovery given supply demand is much more in balance. We have a holding in Western Digital to capture this dynamic.

Past performance is not a guide to the future.
Source: Lipper Limited/Artemis from 31 March to 31 December 2023 for class I Acc USD
All figures show total returns with dividends and/or income reinvested, net of all charges.
Performance does not take account of any costs incurred when investors buy or sell the fund.
Returns may vary as a result of currency fluctuations if the investor's currency is different to that of the class.
Benchmark: S&P 500 TR; the benchmark is a point of reference against which the performance of the fund may be measured. Management of the fund is not restricted by this benchmark. The deviation from the benchmark may be significant and the portfolio of the fund may at times bear little or no resemblance to its benchmark.

Cormac Weldon

Manages:

US equity strategy

Cormac has managed Artemis’ US equity strategies since launch.

View Profile

Chris Kent

Manages:

‘US Select’ strategy

Chris co-manages Artemis’ ‘US Select’ strategy

View Profile

Investment in a fund concerns the acquisition of units/shares in the fund and not in the underlying assets of the fund.

Reference to specific shares or companies should not be taken as advice or a recommendation to invest in them.

For information on sustainability-related aspects of a fund, visit the relevant fund page on this website.

For information about Artemis’ fund structures and registration status, visit artemisfunds.com/fund-structures

Any research and analysis in this communication has been obtained by Artemis for its own use. Although this communication is based on sources of information that Artemis believes to be reliable, no guarantee is given as to its accuracy or completeness.

Any statements are based on Artemis’ current opinions and are subject to change without notice. They are not intended to provide investment advice and should not be construed as a recommendation.

Third parties (including FTSE and Morningstar) whose data may be included in this document do not accept any liability for errors or omissions. For information, visit artemisfunds.com/third-party-data.

Important information
The intention of Artemis’ ‘investment insights’ articles is to present objective news, information, data and guidance on finance topics drawn from a diverse collection of sources. Content is not intended to provide tax, legal, insurance or investment advice and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security or investment by Artemis or any third-party. Potential investors should consider the need for independent financial advice. Any research or analysis has been procured by Artemis for its own use and may be acted on in that connection. The contents of articles are based on sources of information believed to be reliable; however, save to the extent required by applicable law or regulations, no guarantee, warranty or representation is given as to its accuracy or completeness. Any forward-looking statements are based on Artemis’ current opinions, expectations and projections. Articles are provided to you only incidentally, and any opinions expressed are subject to change without notice. The source for all data is Artemis, unless stated otherwise. The value of an investment, and any income from it, can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.